ImmunoPrecise Antibodies Revenue and Competitors

Victoria, CAN

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ImmunoPrecise Antibodies's estimated annual revenue is currently $16.6M per year.(i)
  • ImmunoPrecise Antibodies's estimated revenue per employee is $155,000

Employee Data

  • ImmunoPrecise Antibodies has 107 Employees.(i)
  • ImmunoPrecise Antibodies grew their employee count by 11% last year.

ImmunoPrecise Antibodies's People

NameTitleEmail/Phone
1
ControllerReveal Email/Phone
2
VP Commercial ServicesReveal Email/Phone
3
Head Protein production, ScientistReveal Email/Phone
4
Director Business DevelopmentReveal Email/Phone
5
Creative DirectorReveal Email/Phone
6
Scientific DirectorReveal Email/Phone
7
Director Client RelationsReveal Email/Phone
8
Director Client RelationsReveal Email/Phone
9
Director Client Relations / Quality ManagerReveal Email/Phone
10
Animal Care Program ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$19.7M127-5%$132.7MN/A
#2
$8.8M57-7%$2MN/A
#3
$12.9M835%N/AN/A
#4
$10.2M668%N/AN/A
#5
$101.6M468-11%$94.5MN/A
#6
$22.5M2620%$845.8MN/A
#7
$9.8M34-68%$494.1MN/A
#8
$443.8M67311%$371.2MN/A
#9
$27.6M17819%N/AN/A
#10
$82M3788%$871.5MN/A
Add Company

What Is ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies is a global company highly specialized customer focused life sciences company that provides custom antibody development and immunology services.\n\nOur dedication to advancing antibody development has resulted in cutting-edge immunological innovations such as single-step cloning, Rapid Prime immunization strategies, and recombinant monoclonal technology. \n\nWe pride ourselves on our high customer satisfaction and our clients have grown accustomed to receiving thorough and professional service. We customize your project to generate antibodies that meet your specific needs. Over our 20+ year history, we have gained the trust of a diverse group of customers that include research agencies, universities, biotechnology and pharmaceutical companies of all sizes from around the globe.\n\nImmunoPrecise is pleased to announce its newest line of services, ImmunoProtectâ„¢. With ImmunoProtectâ„¢, the DNA sequence of your mAb is determined and can be used to express your antibody recombinantly. Determining your monoclonal antibody DNA sequence not only provides valuable information about your clone but preserves the information forever. This is critical for unstable and poorly secreting hybridomas and also required for patent applications, antibody engineering and cell line validation.\n\nWe would be happy to discuss your antibody needs, please contact us or visit our website for more information.

keywords:N/A

N/A

Total Funding

107

Number of Employees

$16.6M

Revenue (est)

11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ImmunoPrecise Antibodies News

2022-04-17 - Form 6-K ImmunoPrecise Antibodies For: Apr 22

For the month of April, 2022. Commission File Number: 001-39530. ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter)

2022-04-13 - ImmunoPrecise antibody cocktail shows activity versus ...

ImmunoPrecise Antibodies (NASDAQ:IPA) said its antibody cocktail PolyTope TATX-03 showed strong neutralizing activity against Omicron...

2022-04-06 - Insider Buying: ImmunoPrecise Antibodies Ltd (TSE:IPA ...

Insider Buying: ImmunoPrecise Antibodies Ltd (TSE:IPA) Senior Officer Acquires C$74,875.00 in Stock. Posted by admin on Apr 12th, 2022.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$19.6M10911%N/A
#2
$32.5M1129%N/A
#3
$16.2M1125%N/A
#4
$28.3M113N/AN/A
#5
$25.5M1168%N/A